Supporting Information

Enrofloxacin-Impregnated PLGA Nanocarriers for Efficient Therapeutics and Diminished Generation of Reactive Oxygen Species

Sachin Paudel[1†], *Constantin Cerbu*[2,3†], *Carlos E. Astete*[2], *Stacey M. Louie*[1], *Cristina Sabliov*[2]*, *Debora F. Rodrigues*[1]*

[1]Department of Civil and Environmental Engineering, University of Houston, Houston, TX 77204-4003, USA.

[2]Department of Biological and Agricultural Engineering, Louisiana State University, Baton Rouge, Louisiana 70803, USA.

[3]University of Agricultural Sciences and Veterinary Medicine, Department of Infectious diseases, Cluj-Napoca, Romania

[†]These authors contributed equally

*Corresponding Author, E-mail: CSabliov@agcenter.lsu.edu; 225-578-1055

*Corresponding Author, E-mail: dfrigirodrigues@uh.edu; 713-743-1495

Supporting Information

PLGA nanoparticle stock was prepared on the basis of the measured loading of enrofloxacin in the NPs. Empty PLGA nanoparticles served as control for enrofloxacin loaded PLGA nanoparticles. Nanoparticles stock preparation for reactive oxygen species and cytotoxicity assay is presented here.

1. **Reactive Oxygen Species (ROS)**

PLGA(ENRO) loading capacity: 14.1±2.7 µg/mg

Table S1. Stock preparation of nanoparticles, drug and drug loaded nanoparticles for ROS examination.

Antibiotic/Nanoparticles	Concentration (µg/ml)	Weight (mg)	Volume of PBS (ml)
ENRO	100	1	10
PLGA(ENRO)	100	7	10
PLGA	100	7	10

Further dilution was made for conducting experiment at 50, 1 and 0.5 µg/ml concentrations.

2. **Cytotoxicity Assay**

Table S2. Stock preparation of nanoparticles, drug and drug loaded nanoparticles for MTT assay.

Antibiotic/Nanoparticles	Concentration (µg/ml)	Weight (mg)	Volume of PBS (ml)
ENRO	200	2	10
PLGA(ENRO) NPs	200	14	10
PLGA NPs	200	14	10

Appropriate dilution was made from 200µg/ml stock solutions to obtain the following concentrations: 100, 2, and 1 µg/ml.

3. Linear fit with drug release kinetics



Figure S1. Linear fit of drug release profile with zero-order Kinetic model.



Figure S2. Linear fit of drug release profile with first-order Kinetic model.



Figure S3. Linear fit of drug release profile with Higuchi model.



Figure S4. Linear fit of drug release profile with Korsemeyer-Peppas model.